Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARINA-1 in Bilateral Lung Transplant Patients with CLAD-0
NCT03226431Phase 1Completed
- Sponsor
- Duke University
- Start
- Dec 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ascorbic acid in chronic lung allograft dysfunction (CLAD), sponsored by Duke University. Primary endpoints: Changes in FEV1 at 12 months, Changes in FENO and 1 more. Started Dec 2017; status: completed.
02
Drugs
ascorbic acid
03
Conditions
chronic lung allograft dysfunction (CLAD)
Beyond the preview
Go deeper on NCT03226431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226431.